HFA Cardio Talk copertina

HFA Cardio Talk

HFA Cardio Talk

Di: European Society of Cardiology
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
A proposito di questo titolo
The HFA Cardio Talk provides the opportunity to anyone interested in Heart Failure to receive updates in the field with very specific and diverse topics, go on a deeper subject of an HFA course and to listen to a discussion of key opinion leaders with junior HF specialists. Each month, a new episode lasting approximately 15 minutes and taking the form of a conversation between a member of the HFA Young community and an internationally renowned expert is released. You can also be interested in other ESC podcasts: ESC Cardio Talk, EHRA Cardio Talk, ESC TV Today and much more. Check them out!© European Society of Cardiology Disturbo fisico e malattia Igiene e vita sana Successo personale Sviluppo personale
  • The right chamber in heart failure
    Nov 3 2026

    With Gregorio Tersalvi, Mayo Clinic, Rochester, Minnesota - USA and Irene Lang, Medical University of Vienna, Vienna, Austria.

    In this episode, Gregorio Tersalvi speaks with Irene Lang about the often-underappreciated role of the right ventricle in heart failure. The discussion explores right ventricular adaptation and failure, ventricular-pulmonary vascular coupling, and the challenges of assessing right ventricular function in clinical practice. It also considers how imaging and invasive hemodynamics can improve phenotyping and guide management, as well as current gaps and future directions in the field.

    This 2026 HFA Cardio Talk podcast series is supported by Bayer in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    Mostra di più Mostra meno
    15 min
  • Key insights from the 2026 heart failure guidelines
    Oct 13 2026

    With Floran Sahiti, University Hospital of Wurzburg, Wurzburg - Germany and Marianna Adamo, University and Civil Hospital of Brescia, Brescia – Italy.

    This episode discusses the key changes in the 2026 ESC Guidelines for the management of heart failure with Marianna Adamo, one of the Task Force chairpersons.

    The conversation explores the rationale for removing HFmrEF as a separate phenotype and grouping all patients with an LVEF below 50% as HFrEF. It also covers the new emphasis on stages A to D and earlier treatment to prevent symptomatic heart failure.

    It also examines diagnostic updates, including age-specific NT-proBNP cut-offs and the shift from "acute" to "decompensated" heart failure. Treatment topics include the new framework of foundational, additional and guideline-directed interventional therapies, the place of semaglutide and tirzepatide in obese patients with HFpEF, and the upgrade of LVAD to a Class I recommendation.

    Finally, the episode goes behind the scenes of the consensus process, highlighting which recommendations were most debated within the Task Force.

    Guideline paper: Kober L, Adamo M, Ruwald AC, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. Published online August 28, 2026. doi:10.1093/eurheartj/ehag100

    This 2026 HFA Cardio Talk podcast series is supported by Bayer in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    Mostra di più Mostra meno
    22 min
  • Late-breaking clinical science from ESC Congress 2026
    Sep 16 2026

    With Gregorio Tersalvi, Mayo Clinic, Rochester, Minnesota - USA, Lars Kober and Jawad Haider Butt, Rigshospitalet - Copenhagen University Hospital, Copenhagen - Denmark, Jolie Bruno, Inselspital, Bern University Hospital, University of Bern, Bern - Switzerland, Jorg Hausleiter, LMU University Hospital, LMU Munich, Munich - Germany, Benedikt Norbert Beer, University Medical Center Hamburg-Eppendorf, Hamburg - Germany, Marianna Adamo, University and Civil Hospital of Brescia, Brescia - Italy and Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia.

    In this episode, we discuss the late-breaking clinical science presented at ESC Congress 2026 in Munich, Germany.

    First, Jolie Bruno interviews Lars Kober and Jawad Haider Butt on hydralazine plus isosorbide dinitrate in HFrEF, covering the results of the H-HeFT trial and of the accompanying H-ISDN meta-analysis. H-HeFT compared H-ISDN with placebo in patients with symptomatic heart failure and an ejection fraction of 40% or less, while the meta-analysis pooled three placebo-controlled trials to assess the effect of H-ISDN on mortality and heart failure events.

    Next, Benedikt N. Beer interviews Jorg Hausleiter, who highlights the key findings of TRIC-I-HF, a randomised, open-label trial of transcatheter tricuspid valve repair on top of medical therapy versus medical therapy alone in patients with severe tricuspid regurgitation and heart failure.

    Finally, Novi Yanti Sari interviews Marianna Adamo, who co-chaired the 2026 ESC Guidelines for the management of heart failure and outlines the main novelties of the document.

    This 2026 HFA Cardio Talk podcast series is supported by Bayer in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

    Presenter: Gregorio Tersalvi, Mayo Clinic, Rochester, Minnesota - USA

    Segment 1:

    • Title: H-HeFT: Hydralazine-Isosorbide Dinitrate in HFrEF + H-ISDN Meta-Analysis
    • Results paper: not yet published
    • Design paper: Wiggers H, Køber L, Gislason G, et al. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J. 2021;231:137-146. doi:10.1016/j.ahj.2020.09.020

    Segment 2:

    • Title: TRIC-I-HF (TRICuspid Intervention in Heart Failure)
    • Results paper: Hausleiter J, Stocker TJ, Geisler T, et al. Tricuspid-Valve Intervention in Heart Failure. N Engl J Med. Published online August 30, 2026. doi:10.1056/NEJMoa2606934
    • Design paper: Stocker TJ, Geisler T, Rottbauer W, et al. Rationale and design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) trial. Eur J Heart Fail. 2025;27(10):1895-1904. doi:10.1002/ejhf.3795

    Segment 3:

    • Title: Highlights from the 2026 ESC Guidelines for the management of heart failure
    • Guideline paper: Køber L, Adamo M, Ruwald AC, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. Published online August 28, 2026. doi:10.1093/eurheartj/ehag100
    Mostra di più Mostra meno
    29 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione